Efficacy and Long-Term Outcomes of Direct-Acting Antivirals in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Jeong-Ju Yoo¹, Seul Ki Han², Soon Sun Kim³, Hyun Yang⁴, Eunju Kim⁵, Seong Hee Kang⁶, Young Eun Chon⁷, Eileen L Yoon⁸, Hyun Phil Shin⁹, Sangheun Lee¹⁰, Do Young Kim¹¹, Gi Hyeon Seo¹², Hyung Joon Kim¹³, Hyun Woong Lee¹¹

¹Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.

²Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.

³Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.

⁴Division of Hepatology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

⁵Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Korea.

⁶Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.

⁷Department of Internal Medicine, Institute of Gastroenterology, CHA Bundang Hospital, CHA University, Seongnam, Korea.

⁸Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.

⁹Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea.

¹⁰Division of Hepatology, Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea.

¹¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

¹²VUNO Inc., Seoul, Korea.

¹³Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea.

PubMed PMC DOI PDF

Abstract

BACKGROUND/AIMS: The role of direct-acting antivirals (DAAs) in patients with hepatocellular carcinoma (HCC) remains uncertain due to conflicting data on virologic efficacy and long-term outcomes. METHODS: This meta-analysis investigated studies reporting the sustained virologic response (SVR), recurrence, and overall survival in patients with HCC treated with DAAs. RESULTS: Eighty-eight studies…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.